Prince Mario-Max Schaumburg-Lippe: X9 Ultrasound Earns FDA Breakthrough Designation

For people who rely on hemodialysis, treatment starts with a needle, several times a week, every week. Getting that needle placed well, the same careful way each time, is one of the most important small moments in kidney care. On October 26, 2026, X9, Inc. announced two milestones aimed squarely at that moment: the U.S. Food and Drug Administration has granted Breakthrough Device Designation to the X9 Ultrasound System with Power-Assisted Needle Insertion, and the company has completed ACCESS-2, its second clinical study in patients undergoing hemodialysis.

X9 is a privately held medical technology company based in Wallingford, Connecticut, and launched from the ExploraMed incubator. Its focus is vascular access: using imaging, intelligent guidance, and device-assisted approaches to help clinicians find the right access site and guide needle insertion for hemodialysis cannulation. The designation covers the system’s proposed use in giving healthcare professionals imaging and guidance to identify validated vascular access sites and assist with guided needle insertion.

What Breakthrough Device Designation means

The FDA’s Breakthrough Devices Program is a voluntary program for certain medical devices that may provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. Its purpose is to give patients and healthcare providers more timely access to new devices by speeding up development, assessment, and review, with closer interaction between the company and the agency along the way.

Precision matters here, so let us be exact about what this is and is not. The designation is not FDA clearance or approval, and it does not guarantee future marketing authorization. The X9 System with Power-Assisted Needle Insertion remains an investigational device. It has not been cleared or approved by the FDA and is not available for commercial sale in the United States. What the designation does say is that the FDA sees enough promise in the approach to give it priority attention as development continues. For a small company working on a hard clinical problem, that closer, faster conversation with regulators is a genuine step forward.

ACCESS-2: ten patients, a clean safety result

ACCESS-2 was a prospective, single-center study of the feasibility and safety of the investigational X9 System in patients undergoing hemodialysis through an arteriovenous fistula. Ten patients were enrolled, and the study included multiple dialysis sessions using device-assisted cannulation, so the team gathered experience across repeated treatments rather than a single first try.

The results, as X9 reported them, are encouraging in the way early clinical results should be: clear, modest, and specific. ACCESS-2 demonstrated successful needle placement with the X9 System and subsequent initiation of dialysis, and it achieved the study’s primary safety objective. No serious device-related adverse events were reported, and no other device-related adverse events were reported either. Ten patients is an early study, not a final verdict, and X9 presents it that way, as additional clinical experience building on its initial first-in-human work. That honesty is part of why the update is worth attention.

It is the same pattern we see in the best medical research stories, where careful measurement comes before big claims. Our recent piece on the Ottawa team that found Spriz, a pillar shaping our cells’ powerpacks, followed that rhythm too: a small, well-defined finding, reported precisely, opening a much larger door.

Why consistent access matters so much

Dialysis is a routine that patients build their lives around. Sessions run several times a week, and each one begins with cannulation, the placement of needles into the vascular access. When placement is smooth and consistent, the whole session starts calmer. When it is difficult, the day gets harder before treatment even begins. Clinicians who do this work are highly skilled, and the procedure remains demanding, as X9 CEO Eb Bright put it in the announcement: reliable vascular access is essential to hemodialysis treatment, yet needle insertion remains a demanding procedure.

Bright called the designation an important milestone and said the goal is technology with the potential to make vascular access more consistent and reproducible, with continued clinical development ahead. That word, reproducible, is the heart of it. A tool that helps different clinicians, on different days, find the same good result gives both staff and patients something valuable: confidence at the start of every session.

Support from inside kidney care

The announcement also carried a voice from one of the largest dialysis providers. Steve Phillips, chief strategy officer for DaVita, said his team sees firsthand how even routine parts of the healthcare experience can create discomfort for patients. He said X9 has the potential to change that, not just in kidney care but across healthcare, and that DaVita is energized to support X9 as an investor. Support from an organization that lives inside dialysis clinics every day carries practical weight. It suggests the problem X9 is solving is one clinicians and providers genuinely feel, shift after shift.

That blend of engineering and day-to-day care echoes other health advances we have covered, from imaging tools to new materials, including a redesigned alloy that stays tough at minus 196 degrees, where a laboratory result earns its meaning in real-world use.

What happens next

The path from here is the normal, careful one: continued clinical development, ongoing work with the FDA under the Breakthrough Devices Program, and larger studies to build the evidence base. Nothing about that path is instant, and X9’s announcement does not pretend otherwise. What changed on October 26 is the pace and priority of the conversation, plus a second completed study with successful placements and a clean safety record to bring into it.

For patients, the promise is easy to picture. A calmer start to treatment. A placement that feels routine in the best sense. For clinicians, it is guidance that supports their skill instead of asking them to work around a gadget. And for the wider field, it is one more example of imaging and intelligent guidance finding the places in medicine where a steadier hand helps most. Small moment, several times a week, every week, now with a breakthrough designation behind it. That is a good day’s news for kidney care, and we will follow the next study with real interest, the same curiosity we brought to a single positron held for months opening a new test of the universe: careful work, patiently done, changing what is possible.

Also published on: